BRD9 is frequently amplified in cancer (Table 1, Figure 2) and is a vulnerability in cancer cells with inactivation of SMARCB1 [171] or tumors having an oncogenic SS18-SSX fusion [172]. Here, BRD9 is linked to cancer.